NCATS R21: Preclinical proof-of-concept efficacy studies for rare-disease therapies (includes PK/PD)
NCATS invites R21 applications to run rigorous efficacy studies of a potential therapeutic in an established, validated rare-disease preclinical model, showing proof of concept for further development. Projects should include pharmacokinetic and pharmacodynamic measures alongside efficacy endpoints, and may support additional PK if feasible. Applicants must include a plan for a rare-disease st…
Source
Award
Dates
Eligibility
Keywords
Supporting Links
Documents
Similar Opportunities
Get the full picture on this opportunity
Create a free Scout account to unlock everything you need to decide fast and win the grant.
-
Instant Fit Analysis
Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
-
Deep agency & funder detail
Program context, sub-agency structure, and a full eligibility breakdown.
-
Source links & full documents
Jump straight to the solicitation and download every attachment.
-
Similar opportunities
Discover related funding matched to your work.
Already have an account? Sign In
Trusted by 500+ Happy Customers